Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in <scp>J</scp> apanese people with type 2 diabetes

Abstract

In Japanese people with T2D, more TEAEs were reported with semaglutide than with sitagliptin; however, the semaglutide safety profile was similar to that of other glucagon-like peptide-1 receptor agonists. Semaglutide significantly reduced HbA1c and body weight compared with sitagliptin.